Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Common Equity (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Common Equity data on record, last reported at $274.8 million in Q3 2025.

  • For Q3 2025, Common Equity rose 17.3% year-over-year to $274.8 million; the TTM value through Sep 2025 reached $274.8 million, up 17.3%, while the annual FY2024 figure was $228.8 million, 17.1% up from the prior year.
  • Common Equity reached $274.8 million in Q3 2025 per COLL's latest filing, up from $232.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $274.8 million in Q3 2025 and bottomed at $170.0 million in Q1 2021.
  • Average Common Equity over 5 years is $213.7 million, with a median of $202.9 million recorded in 2021.
  • Peak YoY movement for Common Equity: skyrocketed 62.46% in 2021, then decreased 21.91% in 2022.
  • A 5-year view of Common Equity shows it stood at $202.9 million in 2021, then dropped by 3.98% to $194.8 million in 2022, then rose by 0.3% to $195.4 million in 2023, then rose by 17.1% to $228.8 million in 2024, then grew by 20.09% to $274.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $274.8 million in Q3 2025, $232.2 million in Q2 2025, and $234.4 million in Q1 2025.